Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

F Morabito; S Bringhen; A Larocca; P Wijermans; MV Mateos; P Gimsing; C Mazzone; D Gottardi; P Omede; S Zweegman; JJ Lahuerta; R Zambello; P Musto; V Magarotto; M Schaafsma; A Oriol; G Juliusson; C Cerrato; L Catalano; M Gentile; AI Turel; AM Liberati; M Cavalli; D Rossi; R Passera; Sonia Rosso; M Beksac; M Cavo; A Waage; J San Miguel; M Boccadoro; Pieter Sonneveld; A Palumbo; M Offidani

doi:10.1002/ajh.23641

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

F Morabito, S Bringhen, A Larocca, P Wijermans, MV Mateos, P Gimsing, C Mazzone, D Gottardi, P Omede, S Zweegman, JJ Lahuerta, R Zambello, P Musto, V Magarotto, M Schaafsma, A Oriol, G Juliusson, C Cerrato, L Catalano, M GentileAI Turel, AM Liberati, M Cavalli, D Rossi, R Passera, Sonia Rosso, M Beksac, M Cavo, A Waage, J San Miguel, M Boccadoro, Pieter Sonneveld, A Palumbo, M Offidani

Research output: Contribution to journal › Article › Academic › peer-review

21 Citations (Scopus)

Abstract

Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P<0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32-0.59; P<0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients 75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT. Am. J. Hematol. 89:355-362, 2014. (c) 2013 Wiley Periodicals, Inc.

Original language	Undefined/Unknown
Pages (from-to)	355-362
Number of pages	8
Journal	American Journal of Hematology
Volume	89
Issue number	4
DOIs	https://doi.org/10.1002/ajh.23641
Publication status	Published - 2014

Research programs

EMC MM-02-41-03

Access to Document

10.1002/ajh.23641

http://hdl.handle.net/1765/76349

Cite this

Morabito, F., Bringhen, S., Larocca, A., Wijermans, P., Mateos, MV., Gimsing, P., Mazzone, C., Gottardi, D., Omede, P., Zweegman, S., Lahuerta, JJ., Zambello, R., Musto, P., Magarotto, V., Schaafsma, M., Oriol, A., Juliusson, G., Cerrato, C., Catalano, L., ... Offidani, M. (2014). Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. American Journal of Hematology, 89(4), 355-362. https://doi.org/10.1002/ajh.23641

@article{0acd6f57babe4e1e912e96275d3a7cf3,

title = "Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study",

abstract = "Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P<0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32-0.59; P<0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients 75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT. Am. J. Hematol. 89:355-362, 2014. (c) 2013 Wiley Periodicals, Inc.",

author = "F Morabito and S Bringhen and A Larocca and P Wijermans and MV Mateos and P Gimsing and C Mazzone and D Gottardi and P Omede and S Zweegman and JJ Lahuerta and R Zambello and P Musto and V Magarotto and M Schaafsma and A Oriol and G Juliusson and C Cerrato and L Catalano and M Gentile and AI Turel and AM Liberati and M Cavalli and D Rossi and R Passera and Sonia Rosso and M Beksac and M Cavo and A Waage and {San Miguel}, J and M Boccadoro and Pieter Sonneveld and A Palumbo and M Offidani",

year = "2014",

doi = "10.1002/ajh.23641",

language = "Undefined/Unknown",

volume = "89",

pages = "355--362",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley & Sons Inc.",

number = "4",

}

Morabito, F, Bringhen, S, Larocca, A, Wijermans, P, Mateos, MV, Gimsing, P, Mazzone, C, Gottardi, D, Omede, P, Zweegman, S, Lahuerta, JJ, Zambello, R, Musto, P, Magarotto, V, Schaafsma, M, Oriol, A, Juliusson, G, Cerrato, C, Catalano, L, Gentile, M, Turel, AI, Liberati, AM, Cavalli, M, Rossi, D, Passera, R, Rosso, S, Beksac, M, Cavo, M, Waage, A, San Miguel, J, Boccadoro, M, Sonneveld, P, Palumbo, A & Offidani, M 2014, 'Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study', American Journal of Hematology, vol. 89, no. 4, pp. 355-362. https://doi.org/10.1002/ajh.23641

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. / Morabito, F; Bringhen, S; Larocca, A et al.
In: American Journal of Hematology, Vol. 89, No. 4, 2014, p. 355-362.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

AU - Morabito, F

AU - Bringhen, S

AU - Larocca, A

AU - Wijermans, P

AU - Mateos, MV

AU - Gimsing, P

AU - Mazzone, C

AU - Gottardi, D

AU - Omede, P

AU - Zweegman, S

AU - Lahuerta, JJ

AU - Zambello, R

AU - Musto, P

AU - Magarotto, V

AU - Schaafsma, M

AU - Oriol, A

AU - Juliusson, G

AU - Cerrato, C

AU - Catalano, L

AU - Gentile, M

AU - Turel, AI

AU - Liberati, AM

AU - Cavalli, M

AU - Rossi, D

AU - Passera, R

AU - Rosso, Sonia

AU - Beksac, M

AU - Cavo, M

AU - Waage, A

AU - San Miguel, J

AU - Boccadoro, M

AU - Sonneveld, Pieter

AU - Palumbo, A

AU - Offidani, M

PY - 2014

Y1 - 2014

N2 - Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P<0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32-0.59; P<0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients 75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT. Am. J. Hematol. 89:355-362, 2014. (c) 2013 Wiley Periodicals, Inc.

AB - Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P<0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32-0.59; P<0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients 75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT. Am. J. Hematol. 89:355-362, 2014. (c) 2013 Wiley Periodicals, Inc.

U2 - 10.1002/ajh.23641

DO - 10.1002/ajh.23641

M3 - Article

C2 - 24273190

SN - 0361-8609

VL - 89

SP - 355

EP - 362

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 4

ER -